Institution statistics

F. HOFFMANN-LA ROCHE AG - Switzerland 

Ranking results:

Past rankings:
2019
Criterium:Position:
Overall Score:500-600
Total Project Funding per Partner:> 1000
Total Number of Projects:400-500
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:700-800
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:700-800
Total Project Funding per Partner:700-800
Total Number of Projects:68
Total Project Funding:700-800
Networking Rank (Reputation):700-800
Networking Rank (Reputation):700-800
Partner Constancy:46
Project Leadership Index:75
Diversity Index:41
Ranking timeline:

European project participation (2010-01-01 - 2021-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 39
As coordinator: 0
As participant: 39
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 6.265.845 562.553 2
2020 0 32.597.381 0 4
2019 0 108.849.548 702.379 8
2018 0 130.275.644 0 4
2017 0 43.440.356 0 5
2016 0 64.482.031 0 7
2015 0 5.972.496 0 1
2014 0 5.998.346 124.247 1
2013 0 15.918.137 762.895 2
2012 0 17.316.160 201.181 3
2011 0 3.496.556 253.634 1
2010 0 1.762.399 141.847 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
NOVARTIS PHARMA19
JANSSEN PHARMACEUTICA NV17
ELI LILLY AND COMPANY LIMITED15
PFIZER LIMITED14
STICHTING KATHOLIEKE UNIVERSITEIT8
UCB BIOPHARMA8
UNIVERSITY COLLEGE LONDON8
BAYER7
CHARITE UNIVERSITAETSMEDIZIN BERLIN7
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM7
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT7
MERCK SHARP & DOHME CORP7
SANOFIAVENTIS7
SANOFIAVENTIS RECHERCHE & DEVELOPPEMENT7
TAKEDA DEVELOPMENT CENTRE EUROPE7
ASTRAZENECA6
BAYER AKTIENGESELLSCHAFT6
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE6
KATHOLIEKE UNIVERSITEIT LEUVEN6
ABBVIE INC5
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG5
EBERHARD KARLS UNIVERSITAET TUEBINGEN5
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V5
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE5
KAROLINSKA INSTITUTE5
KING'S COLLEGE LONDON5
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN5
STICHTING VU5
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL5
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE5
THE UNIVERSITY OF EDINBURGH5
UNIVERSITY OF NEWCASTLE UPON TYNE5
GOETEBORGS UNIVERSITET4
H LUNDBECK AS4
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER4
RIJKSUNIVERSITEIT GRONINGEN4
SERVICIO MADRILENO DE SALUD4
STICHTING VUMC4
UNIVERSITAIR MEDISCH CENTRUM UTRECHT4
UNIVERSITEIT GENT4
UNIVERSITEIT MAASTRICHT4
ACADEMISCH ZIEKENHUIS LEIDEN3
ALZHEIMER EUROPE3
ARTTIC3
ASTRAZENECA AB3
COMMISSARIAT A L'ENERGIE ATOMIQUE3
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK3
EUROPEAN CANCER PATIENT COALITION3
EUROPEAN MOLECULAR BIOLOGY LABORATORY3
FORUM DES PATIENTS EUROPEENS3
FUNDACIO SANT JOAN DE DEU3
INSTITUT DE RECHERCHES SERVIER3
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN3
MEDIZINISCHE HOCHSCHULE HANNOVER3
MEDIZINISCHE UNIVERSITAET WIEN3
MEDIZINISCHE UNIVERSITAT INNSBRUCK3
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE3
NOVO NORDISK3
ORION OYJ3
REGION HOVEDSTADEN3
STICHTING BURO ECNP3
SYNAPTOLOGICS BV3
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD3
THE UNIVERSITY OF LIVERPOOL3
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK3
UNIVERSITY OF GLASGOW3
UPPSALA UNIVERSITET3
ACADEMISCH ZIEKENHUIS GRONINGEN2
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN2
AMGEN LIMITED2
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
BIOGEN IDEC LIMITED2
BIOSCI CONSULTING BVBA2
CERTARA UK LIMITED2
CONCENTRIS RESEARCH MANAGEMENT2
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS2
COVANCE LABORATORIES2
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH2
EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH2
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE2
EUROPEAN PATIENTS' FORUM2
EURORDIS EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION2
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES2
FUNDACION HOSPITAL LA FE2
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD2
GRUNENTHAL2
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE2
INSPHERO2
INSTITUT GUSTAVE ROUSSY2
INSTITUT PASTEUR2
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES2
JDRF INTERNATIONAL2
KAROLINSKA INSTITUTET2
KOBENHAVNS UNIVERSITET2
KUNGLIGA TEKNISKA HOEGSKOLAN2
LEIDS UNIVERSITAIR MEDISCH CENTRUM2
LHASA LIMITED2
LIFE AND BRAIN2
LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE2
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV2
Constancy:

Total number of partners:867

Partner loyalty:
Frequent Partner: (> 2 projects): 348
Rare Partner: 519

Frequent / Rare Partner Ratio: 0.67

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES5
SOCIAL AND ECONOMIC CONCERNS2
INDUSTRY AND TECHNOLOGY2
RTD HORIZONTAL TOPICS1

Project overview:

Start dateProjectacronymrolefundingpartners
2021-01-01Drug Absorption in Geriatric Patients and Older People: a training network innovating drug development for the advanced age population AGePOPparticipant2.790.4436
2021-01-01A fully integrated, animal-free, end-to-end modelling approach to oral drug product development InPharmaparticipant3.475.40211
2020-11-01Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment Gravitate-Healthparticipant9.280.00040
2020-10-01H2O Health Outcomes Observatory H2Oparticipant10.476.68723
2020-09-01Prioritisation and Risk Evaluation of Medicines in the EnviRonment PREMIERparticipant4.550.00025
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69429
2019-12-01Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies imSAVARparticipant10.999.31628
2019-11-01Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases IDEA-FASTparticipant20.997.52346
2019-11-01Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis MIRIADEparticipant4.034.56511
2019-11-01Virtual IoT Maintenance System VIMSparticipant2.345.8304
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00022
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19270
2019-03-01Efficiently Networking European Neurodegeneration Research NEURONETparticipant1.199.12510
2019-02-01Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease TransBioLineparticipant13.999.99827
2018-10-01European Training Network to Diagnose, Understand and Treat Stargardt Disease, a Frequent Inherited Blinding Disorder StarTparticipant3.776.71415
2018-06-01Autism Innovative Medicine Studies – 2 – Trials AIMS-2-TRIALSparticipant54.999.99948
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00048
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-09-01Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management eTRANSAFEparticipant20.000.00027
2017-09-01Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076 MACUSTARparticipant8.025.00013
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 ITCC-P4participant7.370.00021
2016-11-01Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 ROADMAPparticipant3.998.25026
2016-11-01Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976 PHAGOparticipant8.838.00020
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-04-01Psychiatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916 PRISMparticipant8.080.00023
2016-03-01FRAGments training NETwork FRAGNETparticipant3.842.48213
2016-01-01An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century EU-ToxRiskparticipant27.798.29941
2016-01-01Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders COSYNparticipant5.925.00014
2015-05-01Exploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways EYE-RISKparticipant5.972.49612
2014-02-01Translating neuroimaging findings from research into clinical practice PSYSCANparticipant5.998.34615
2013-10-01Deciphering inter- and intracellular signalling in schizophrenia IN-SENSparticipant3.918.13813
2013-10-01Hepatic and Cardiac Toxicity Systems modelling HECATOSparticipant11.999.99914
2012-05-01New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier TRANS-INTparticipant8.000.00017
2012-02-01Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer RESPONSIFYparticipant5.990.19512
2012-02-01Scalable, Standard based Interoperability Framework for Sustainable Pro-active Post Market Safety Studies SALUSparticipant3.325.96510
2011-04-01Biomedical engineering for cancer and brain disease diagnosis and therapy development EngCaBraparticipant3.496.5569
2010-07-01Histopathologic and Mechanistic Assessment of Angiogenesis Inhibitor Related Toxicities: A Cross-Sectoral, Multi-disciplinary Approach ANGIOTOXparticipant1.762.39910
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum